Floatz logo

SX682

Paranasal Sinus Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Paranasal Sinus Neoplasm cohort.

Asset / SponsorPhaseRating
Docetaxel
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

SX682 is also rated in:

metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →